What stem cell therapy is FDA approved?

Only a small number of stem cell products are FDA-approved, and none are approved to treat joint pain or aging. The U.S. Food and Drug Administration has cleared blood-forming stem cell transplants and a handful of specific cell therapies for serious blood and immune disorders. Products marketed for knees, backs, hair loss, or “anti-aging” are not on that list.

This guide names the approved products, explains what isn’t approved, and shows you how to verify a clinic’s claims. For more context, see our guide to whether stem cell therapy is legal in the US.

What “FDA approved” actually means

FDA approval means a product passed clinical trials and carries a specific approved use. The FDA reviews safety and effect data, then approves the product for a named condition. Approval is tied to that use, not to stem cells in general.

This matters because clinics blur the line. A product approved for one blood disease is not approved for a knee. No manufacturer has completed the clinical trials FDA approval requires for a joint or anti-aging product, which is why nothing on that list exists yet.

The FDA-approved stem cell products

The FDA has approved two broad groups: blood-forming transplants and a short list of named cell products. Here is the 2026 picture.

Ryoncil is the first approved mesenchymal stromal cell therapy, which matters because “mesenchymal stem cells” is the exact phrase orthopedic clinics use. Its approval is only for a pediatric transplant complication. Tregzi was approved in June 2026 for use alongside donor transplants.

What the FDA has NOT approved

The FDA has not approved any stem cell product for orthopedic pain, aging, or most chronic conditions. This is the list that surprises patients, so read it carefully.

• Knees, hips, shoulders, and other joints. No approved stem cell product exists for arthritis or joint injury.
• Back and spine pain. Not approved.
• Anti-aging, “wellness,” and IV longevity infusions. Not approved.
• Autism, MS, Parkinson’s, COPD, and similar claims. Not approved, and the FDA has warned specifically about these marketing claims.
• Hair loss and cosmetic “stem cell facials.” Not approved; many use PRP or exosomes, not stem cells.

If a clinic offers any of the above and calls it FDA approved, the claim is wrong.

FDA approved vs registered vs “in a trial”

Three phrases get used to sound official, and only one is approval. Knowing the difference protects you from a common sales tactic.

FDA approved means the product cleared review for a named use. This is the real thing.

FDA registered or FDA listed only means a facility filed paperwork saying it handles tissue. The FDA states plainly that registration is not endorsement or approval. Any tissue clinic can register.

“Part of an FDA trial” may be legitimate if there is a real Investigational New Drug filing. But a genuine trial does not charge large fees for unproven treatment and registers on ClinicalTrials.gov. Ask for the trial’s registration number and check it.

RMAT Designation Is Not the Same as Approval

RMAT designation does not mean a product is FDA approved. It only means the FDA agreed a product deserves a faster review track.

The FDA created Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act in 2016 for cell, tissue, and gene therapies aimed at serious conditions. A sponsor requests it once early trial results suggest a product might work, and the FDA rules within 60 days. The designation attaches to that one investigational product. It does not cover a whole treatment category or a specific clinic.

The status buys a sponsor faster, more frequent meetings with the FDA’s Center for Biologics Evaluation and Research, plus the option to file approval evidence in pieces through a rolling review. Neither benefit is approval. A designated product can run several more clinical trials and still never clear the bar Ryoncil and Tregzi already cleared.

A clinic that points to RMAT designation has confirmed only that the FDA agreed the idea deserved a faster look. Check the product’s current status on the FDA’s approved list instead of its designation history.

The Clinical Trial Pipeline Behind Every Biological Approval

Every regenerative medicine product seeking federal approval must clear a formal testing pipeline that begins with an Investigational New Drug (IND) application and advances through three sequential clinical trial phases before agency review.

Before any human testing can begin, the sponsor must submit an IND application to the Food and Drug Administration (FDA). This submission provides preclinical laboratory data, animal study findings, manufacturing controls, and detailed clinical protocols designed to protect study participants from unreasonable risk. Only after the FDA reviews the application and allows it to take effect can investigators recruit patients for human trials.

• Phase 1 clinical trials: Enroll 20 to 100 healthy volunteers or individuals with the target condition. These trials last several months to establish basic safety, identify side effects, and determine safe dosage ranges. Approximately 70 percent of candidate therapies advance from this initial phase.
• Phase 2 clinical trials: Enroll up to several hundred participants diagnosed with the condition. These studies run from several months up to 2 years to measure initial efficacy and monitor short-term adverse reactions. Roughly 33 percent of tested products successfully advance past this stage.
• Phase 3 clinical trials: Enroll 300 to 3,000 participants with the condition across multiple study sites. These studies last from 1 to 4 years to confirm clinical efficacy, monitor adverse events in broader populations, and compare the intervention against existing standards of care. Between 25 and 30 percent of evaluated treatments clear this final phase.

Because cellular therapies are classified as biological products, a sponsor that completes Phase 3 files a Biologics License Application (BLA) rather than the New Drug Application (NDA) used for conventional chemical drugs. Under the performance goals of the Prescription Drug User Fee Act (PDUFA), the FDA targets a 10-month review timeline for standard BLA submissions and a 6-month review for applications granted priority status.

If a commercial provider claims its procedures are part of an ongoing clinical study to justify out-of-pocket charges, verify the protocol using our guide to clinical trials versus cash clinics. Every approved cellular product, including Ryoncil and Tregzi, completed this entire trial and licensing process, and no biological intervention sold for arthritic joints, spinal discs, or systemic anti-aging has cleared it.

The mesenchymal stem cell trap

The phrase “mesenchymal stem cells” is approved for one narrow product, not for the injections most clinics sell. Ryoncil is a mesenchymal stromal cell therapy, and clinics lean on that fact. They imply their fat-derived or cord-derived joint injection shares Ryoncil’s approval. It does not, and clinic-quoted success rates for these unapproved injections are not held to the same evidence standard Ryoncil had to clear.

Approval is product-specific and use-specific. A shared cell family means nothing legally. When a clinic points to Ryoncil to justify a knee injection, that is a signal to slow down, not to trust.

What about my own cells, same day?

A same-day procedure using your own minimally processed cells sits in a gray zone, not a clear approval. Some clinics draw your bone marrow or fat, spin it, and re-inject it in one visit. They argue this fits the tissue exemption because the cells are barely handled and go back into your body.

The tissue exemption comes from a specific split in FDA rules. A 361 product is minimally processed tissue put back to do its original job, such as bone marrow returned to bone marrow, and it can skip the approval process. A 351 product is regulated as a biologic drug, the same category Ryoncil and Tregzi went through, and it must clear clinical trials before sale.

The FDA may treat some of these procedures as exempt, but many still fail the homologous-use test. Injecting fat-derived cells into a joint to change cartilage is often not the cells’ original job. So “your own cells” does not equal “FDA approved,” and it does not remove the risk. It only changes which rule the clinic is leaning on.

Ask the clinic to state plainly whether the product is FDA approved, exempt under the tissue rule, or unapproved. The answer for orthopedic and anti-aging use is almost never “approved.”

How to verify an approval yourself

You can confirm any approval in a few minutes using the FDA’s own lists. Do this before you pay anything.

1. Open the FDA’s approved cellular and gene therapy products page.
2. Look for the exact product name and its approved use.
3. If the clinic names a “trial,” find its number on ClinicalTrials.gov.
4. If nothing matches the product and your condition, it is not FDA approved.

A clinic that cannot point you to a real listing is telling you the answer by its silence. Our how to vet a clinic guide expands this into a full checklist, and our insurance coverage guide explains why unapproved status also means you pay out of pocket. If you are weighing treatment outside the US, our guide to stem cell regulation by country covers how Mexico, Europe, and other regulators handle approval differently.

Recent FDA enforcement against unapproved sellers

The FDA backs the approval list above with active enforcement, not just published guidance. Two 2026 warning letters show what that looks like in practice.

In February 2026, the FDA sent a warning letter to Dynamic Stem Cell Therapy over an umbilical-cord-derived product marketed for use in patients other than the cell donor. The agency classified the marketing as misbranding under the Federal Food, Drug, and Cosmetic Act.

In August 2026, the FDA sent a warning letter to R3 Medical Companies, a Beverly Hills, California business selling exosome products under the names ReBellaXO and ReBellaXOL. The clinic’s position was that the products fall outside biologic regulation because they contain no cells, only cell-derived exosomes. The FDA rejected that argument and treated the products as unapproved biologics.

Neither letter is an isolated case. The FDA has sent similar letters to stem cell and exosome sellers every few months since 2024, and a warning letter does not require a lawsuit or a court finding first. Search the FDA’s warning letters database by clinic or manufacturer name before you pay a deposit.

The bottom line on FDA approval

Stem cell therapy is FDA approved only for blood and immune uses and a few named products like Ryoncil and Tregzi. It is not approved for knees, backs, hair, or anti-aging in 2026. Learn the difference between approved, registered, and “in a trial,” and verify every claim on the FDA’s own site. When the approved list and your condition do not match, staying inside that list is the surest way to avoid the risk. Choosing anything outside it is still your call, but it means knowingly accepting a risk the FDA has not evaluated.

Frequently asked questions

Is any stem cell therapy FDA approved in 2026?

Yes. The FDA has approved blood-forming stem cell transplants and a small set of named cell products, such as Ryoncil and several cord-blood products. None are approved for knee arthritis, back pain, or anti-aging.

Is stem cell therapy for knees FDA approved?

No. As of 2026 the FDA has not approved any stem cell product for knee arthritis or other orthopedic pain. Clinics offering knee injections sell them under a tissue exemption or as unapproved products.

What does 'FDA registered' mean on a clinic's website?

FDA registered is not FDA approved. Registration only means a facility told the FDA it handles human tissue. It does not mean the product was reviewed, tested, or cleared for any use. Treat the two phrases as completely different.

Is Ryoncil an FDA-approved stem cell therapy?

Yes. Ryoncil (remestemcel-L) is an FDA-approved mesenchymal stromal cell product. It is approved for steroid-refractory acute graft-versus-host disease in children, not for joints or general wellness.

Are cord blood or 'umbilical stem cell' injections FDA approved?

Only for specific blood-reconstitution uses. The FDA has approved certain cord-blood products to rebuild the blood system after transplant. Cord or umbilical products injected into joints or given by IV for other conditions are not approved.

How can I verify an FDA approval myself?

Search the FDA's approved cellular and gene therapy products list and the drug approval database. If a specific product and use are not listed there, it is not FDA approved, no matter what the clinic's brochure says.

What's the difference between FDA approved and FDA cleared?

'FDA approved' and 'FDA cleared' are different regulatory pathways. Approval covers drugs and biologics, including stem cell products, and requires clinical trials that prove safety and effectiveness for a named use. Clearance is a device pathway that compares a new device to one already for sale, and no stem cell product itself is FDA cleared.

If a treatment isn't FDA approved, does that mean it doesn't work?

No, not necessarily. An unapproved product may have failed a clinical trial, or it may never have been tested in one at all. Most stem cell products sold for joints, backs, or anti-aging fall into that second group, so no one actually knows whether they work. See our clinical trials vs cash clinics guide for how to check which group a specific clinic's offer falls into.

Why hasn't the FDA approved stem cell therapy for joints or pain?

The FDA requires large, controlled clinical trials proving a product is both safe and effective for a specific use, and no sponsor has completed that process for a joint or pain injection. Approval is granted product by product and use by use. Running those trials and filing for review costs far more than selling the injection now under a tissue exemption or off-label, so most sellers skip it. Until a sponsor does that work and the FDA's approved list adds a joint product, every injection sold for arthritis or pain stays unapproved by definition.

Why is stem cell therapy illegal in the United States?

Strictly, most stem cell therapy for joints, pain, or anti-aging isn't 'illegal' as a blanket rule. It's unapproved. Selling an unapproved biologic drug for an unauthorized use is what violates federal law, and the FDA has sued and issued warning letters and injunctions against specific clinics on that basis. That is different from a flat ban: the same cell type can be legally used for an FDA-approved purpose, like a blood-cancer transplant, while being sold illegally for a joint or IV "wellness" use. See our legality hub for how this plays out state by state.

Is there an official list of FDA-approved stem cell clinics?

No such list exists, because FDA approval applies to a specific product for a specific use, not to a clinic as a whole. A clinic can register with the FDA as a tissue establishment, which only means it filed paperwork saying it handles human tissue, and that registration says nothing about whether any product it sells is approved. Check the product name, not the clinic name, against the FDA's approved cellular and gene therapy products list to see whether a specific treatment is covered.

Are nasal-spray or intranasal exosome products FDA-approved?

No, the Food and Drug Administration (FDA) has not approved any nasal-spray or intranasal exosome product for any therapeutic use. Under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, exosomes used to treat diseases are regulated as drugs and biological products. That classification requires premarket review and approval regardless of delivery route, including topical formulations, injections, and nasal sprays. In a public safety notification issued on December 6, 2019, the FDA warned about unapproved exosome products after multiple patients in Nebraska suffered serious adverse events from treatment.